{"id":1408,"date":"2023-03-03T13:10:00","date_gmt":"2023-03-03T13:10:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-to-showcase-at-the-2023-acc-congress-2\/"},"modified":"2024-08-06T12:24:46","modified_gmt":"2024-08-06T12:24:46","slug":"acarix-to-showcase-at-the-2023-acc-congress-2","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-to-showcase-at-the-2023-acc-congress-2\/","title":{"rendered":"Acarix to showcase at the 2023 ACC congress"},"content":{"rendered":"
\n

Acarix, a leader in acoustic and AI-based cardiac diagnostics, will demonstrate the value of its CADScor System during the American College of Cardiology (ACC) Annual Scientific Session and Expo and World Congress of Cardiology on March 4-6, 2023, in New Orleans, Louisiana.<\/strong><\/p>\n<\/div>\n

\n

"This is an important event for Acarix in the US, and we are excited to be demonstrating the CADScor System to many of the 17,000 attendees\u201c, said Helen Ljungdahl Round, Acarix President, and CEO. "We are showcasing at the ACC meeting to present to physicians how the CADScor System can be incorporated into their workflow for chest pain patients as a first-line diagnostic aid to rule out significant coronary artery disease, and bring value to millions of patients, physicians and health care systems".<\/p>\n

In September 2022, Acarix and ACC entered strategic collaboration agreement to help accelerate the roll-out of CADScor System in the US market. Under this agreement, ACC will provide clinical and scientific expertise to Acarix and develop a clinical framework for use of CADScor System in upstream cardiac diagnostics, which is planned for later this year.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46\u00a0730 770283, email helen.round@acarix.com<\/a>\u00a0
Christian Lindholm, CFO, phone +46\u00a0705 118333, email christian.lindholm@acarix.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor\u00aeSystem is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se<\/a>) is Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a>.\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix to showcase at the 2023 ACC congress<\/a><\/p>\n<\/div>\n